The FDA’s adverse event reporting system has logged more than 1,700 individual reports involving compounded semaglutide and tirzepatide, according to an analysis of agency data by Drug Discovery Trends. The reports, recorded through May 31, 2026, include over 990 reports tied to compounded semaglutide and more than 730 for compounded tirzepatide.
The data surfaces as the FDA advances efforts to permanently exclude commercially available GLP-1 medications from the 503B bulk compounding list, a move that would restrict outsourced facilities from compounding copies of these drugs. The accumulation of documented adverse event reports provides regulators with real-world data that may inform that ongoing process.
What happened
Drug Discovery Trends analyzed FDA adverse event data and identified more than 1,700 reports associated with compounded versions of semaglutide and tirzepatide. The reports span a range of adverse outcomes, though the specific nature and severity of individual cases was not detailed in the analysis.
The FDA has noted that adverse event reports do not establish causation between a product and an outcome. The agency also cautioned that the figures are likely undercounts, because many state-licensed pharmacies are not required to submit adverse event reports to the federal system. This means the actual number of events involving compounded GLP-1 products could be higher than the documented total.
Why it matters
The dataset matters for several reasons. First, it provides documented evidence of real-world harms potentially linked to compounded GLP-1 products, which regulators can cite in rulemaking and enforcement actions. The FDA has proposed excluding semaglutide and tirzepatide from the 503B bulk compounding list, and adverse event data may strengthen the agency’s justification for that restriction.
Second, the reports could complicate legal and defense strategies for compounding pharmacies and telehealth platforms that prescribe or dispense compounded GLP-1 medications. Documented adverse events may factor into litigation, regulatory scrutiny, and malpractice considerations.
Third, the data highlights a reporting gap. Because many state-licensed pharmacies operating under 503A are not required to report adverse events to the FDA, the full scope of safety issues associated with compounded GLP-1s remains uncertain.
What to watch next
- Whether the FDA finalizes its proposal to exclude commercially available GLP-1s from the 503B bulk compounding list.
- Whether additional adverse event data accumulates as reporting continues through 2026.
- How compounding pharmacies and telehealth platforms respond to mounting regulatory and legal pressure around compounded GLP-1 products.
- Whether any legislative or regulatory changes address the reporting gap for state-licensed pharmacies.
Sources
Industry information only. Not medical or legal advice.
